Pharma CEO Series

An Evening with Zogenix's CEO Stephen Farr, Ph.D.and Bradley Galer, MD, Chief Medical Officer

stephen-farrStephen J. Farr, Ph.D. is one of the co-founders, a member of board of directors and has served as Chief Executive Officer since April 2015, leading the strategy on developing drugs in rare orphan neurological disorders. In his original role as President and Chief Operating Officer since the founding of Zogenix in 2006, Dr. Farr led the development and FDA approval of the Company’s first two drug products.  Prior to starting Zogenix, Dr. Farr held positions of increasing responsibility at Aradigm Corporation from 1995 to 2006.  His last position was Aradigm’s Sr. Vice President and Chief Scientific Officer, with responsibility for research and development as well as business development.  From 1986 to 1994, Dr. Farr was a tenured professor at the Welsh School of Pharmacy, Cardiff University, United Kingdom, concentrating in the areas of biopharmaceutics. While there, he built an internationally recognized research group working in drug delivery science with a focus on pulmonary drug delivery. Dr. Farr is a member of the board of directors of SteadyMed (NASDAQ: STDY) and two private companies, Oscillari, LLC and Flow Pharma, Inc.  He is author/co-author of over 180 scientific publications and patents and retains his academic interests as adjunct Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, Richmond, USA.  Dr. Farr received a BSc (Hons) Pharmacy degree from De Montfort University, UK and held his Ph.D. degree in Pharmaceutics from the University of Wales.

bradley-galerBradley S. Galer, M.D., has served as Zogenix Executive Vice President and Chief Medical Officer since December 2013. Prior to joining Zogenix, Dr. Galer served as President at Nuvo Research, a specialty pharmaceutical company with three commercialized topically delivered pain products. From 2000-2005 Dr. Galer was Endo Pharmaceuticals’ Senior Medical Officer and Group Vice President, Scientific Affairs. Prior to joining industry, Dr. Galer was on faculty at University of Washington and Albert Einstein College of Medicine. He has published over 200 articles in peer review journals and textbooks. Dr. Galer received his medical doctorate and a neurology residency from Albert Einstein in New York and two Fellowships, at Memorial Sloane-Kettering in New York and University of California San Francisco.

March 28, 2018
6:30 - 8:30 PM

Gibson Dunn Law Firm
555 Mission Street
Suite 3000
San Francisco, CA 94105

$25.00 HCSF members
$25.00 HBSHAA members
35.00 non-member

No refunds 72 business hours prior to the event
Refunds subject to $5 processing fee

Click here for tickets!

Anupam Agarwal, MPH ’05, VP Membership